Camber1jpj (Camber1jpg)
Tadalafil
Product Images NDC 50436-6440
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50436-6440). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Label Image (Lbl504366440)
Tadalafil 5 mg tablets label from Unit Dose Services, NDC 50436-6440. It indicates a carton containing one tablet per unit dose pouch, with a total package count of 1,890 pouches. The label includes storage instructions, manufacturer details in the US and India, re-packager information, and a warning to keep out of reach of children.*
Tadalafilfigure1.jpg (Tadalafilfigure1)
Four line graphs depicting the difference in blood pressure measurements (mmHg) between Tadalafil and placebo over time in hours. The charts show standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure changes over approximately 96 hours, with error bars indicating variability at each time point.*
Tadalafilfigure2.jpg (Tadalafilfigure2)
This image contains two line graphs comparing the effects of Tadalafil 20 mg combined with doxazosin 8 mg versus placebo combined with doxazosin 8 mg on systolic blood pressure (mmHg) over 24 hours post-dose. The top graph shows standing systolic blood pressure, the bottom graph shows supine systolic blood pressure, both measured at multiple time points.*
Tadalafilfigure4.jpg (Tadalafilfigure4)
A line graph showing the effect on systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo. The graph compares four groups: 20 mg tadalafil with 8 mg doxazosin at 08:00, placebo with 8 mg doxazosin at 08:00, 20 mg tadalafil with 8 mg doxazosin at 20:00, and placebo with 8 mg doxazosin at 20:00, illustrating blood pressure changes over time after dosing.*
Tadalafilfigure5.jpg (Tadalafilfigure5)
A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for different dosing regimens. The graph compares single 20-mg dose, single 5-mg dose, and once-daily 5-mg tadalafil after 5 consecutive days. Error bars indicate variability at each time point across approximately 120 hours.*
Tadalfilfigure6.jpg (Tadalafilfigure6)
A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment with Tadalafil 5 mg versus placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline in IPSS score. Tadalafil shows a greater decrease in score compared to placebo throughout the treatment period, with statistical significance indicated at p<0.01.*
Tadalafilfigure7.jpg (Tadalafilfigure7)
A line graph depicting the change from baseline in IPSS Total Score over a treatment duration of 12 weeks for Tadalafil 5 mg compared to placebo. The graph shows that Tadalafil reduces the IPSS score more significantly than placebo, with a marked difference noted at weeks 1 and 4. A statistical significance marker indicates p<0.01 at week 4.*
Tadalafilfigure8 (Tadalafilfigure8)
A line graph titled 'Weeks of Therapy' showing least-squares mean changes from baseline over 26 weeks for Tadalafil/Finasteride versus Placebo/Finasteride treatment groups. Data points illustrate a decrease over time, with annotations indicating statistical significance (p<0.001 and p<0.05).*
Tadalfilfigure9.jpg (Tadalafilfigure9)
A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment, showing one line for Tadalafil and another for Placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline in IPSS Total Score. Statistical significance is indicated for Tadalafil versus Placebo.*
Tadalafilstructure.jpg (Tadalafilstructure)
Chemical structure of the active ingredient tadalafil, showing its molecular components arranged with multiple rings and functional groups including a methyl group, carbonyl groups, and a fused heterocyclic system.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
